SCHEMBL23208227

SCHEMBL23208227

O=C(Nc1ccc(C(F)(F)F)cc1)Nc1c[nH]c2ccc(-c3ccc(CO)cc3)cc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 7/20 0.62
▸ GOT1 P17174 1/20 0.46
▸ EPHX2 P34913 1/20 0.46
▸ NHERF1 O14745 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LYN P07948 2/20 0.42
▸ IKBKB O14920 1/20 0.42
▸ CHUK O15111 1/20 0.42
▸ IGF1R P08069 1/20 0.42
▸ SYK P43405 1/20 0.42
▸ MAPK8 P45983 1/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ MTOR P42345 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ ICMT O60725 1/20 0.42
▸ TRPV1 Q8NER1 1/20 0.42
▸ PLK4 O00444 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23207913 0.91 STING1 (0.62) STING1GOT1EPHX2MEN1KMT2A
SCHEMBL30195943 0.91 STING1 (0.62) STING1GOT1EPHX2MEN1KMT2A
SCHEMBL23207910 0.91 STING1 (0.61) STING1GOT1EPHX2LYNIKBKB
SCHEMBL23208228 0.89 STING1 (0.59) STING1GOT1EPHX2MEN1KMT2A
SCHEMBL23207756 0.88 STING1 (0.56) STING1GOT1EPHX2LYNIKBKB
SCHEMBL23207945 0.88 STING1 (0.66) STING1GOT1EPHX2MEN1KMT2A
SCHEMBL23167861 0.88 STING1 (0.73) STING1GOT1EPHX2MEN1KMT2A
SCHEMBL23208024 0.88 STING1 (0.58) STING1GOT1EPHX2MEN1KMT2A
SCHEMBL23208063 0.88 STING1 (0.58) STING1GOT1EPHX2MEN1KMT2A
SCHEMBL23207649 0.87 STING1 (0.65) STING1GOT1EPHX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
WO-2021067801-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885GOT1 926/4885EPHX2 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback